Vacc 4x

Drug Profile

Vacc 4x

Alternative Names: HIV vaccine Vacc-4x; Vacc-4x; ™Kick, Kill and Boost strategy - Bionor Holding

Latest Information Update: 16 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bionor Immuno
  • Developer Bionor Holding; Bionor Pharma; Celgene Corporation; Eurocine; Oslo University Hospital; University of Bergen; University of Oslo
  • Class AIDS vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 30 Mar 2017 Bionor receives grant from the Research Counsil of Norway under a Programme for User-driven Research-based Innovation for vacc 4x development in HIV infections
  • 15 Sep 2016 Bionor plans a triple combination clinical trial BIONAB for HIV-1 infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top